one biotech best execut stori full display strong
increment posit share describ strong
across-the-board top-/bottom-lin beat/rais obviou indic
strength think import indic ultomiri convers
pipelin progress continu effici capit deploy short manag
done sinc take helm year ago execut despit share remain range-
bound morn case point larg see unfound concern
tail trajectori soliris/ultomiri abil diversifi away franchis
money remain manag abil continu alreadi
impress record execut continu think patient investor reward
key competit concern fall waysid remain among favorit larg cap
anoth quarter anoth beat/rais point upsid matter
total revenu beat consensu pjc non-
ep beat consensu pjc primarili driven
expect guidanc rais consecut increas includ
revenu increas previous driven rais soliris/ultomiri
sale guidanc ep guidanc also rais midpoint
previous ahead consensu pjc
overhang like lift loom threat eu soliri biosimilar
concern call focus sep epo decis soliri com/method
use patent regardless decis manag see least runway
drive eu soliris-to-ultomiri convers pnh ahu approv expect
similar pace us convers mo post-launch numer better
efficaci complianc friendli dose schedul soc see littl evid
even discount price payer would opt inferior option avail
pipelin progress continu rumor syntimmun demis greatli
exagger pipelin diversif remain top prioriti new trial
ultomiri hsct-tma expect derisk posit label use
off-set time anti-fcrn move back modestli waiha initi
gmg initi pend subq data follow cmc-
relat issu weve investor ask write syntimmun
acquisit wed view posit rel expect
remain top pick continu domin complement franchis
manag on-going record execut continu like setup
chang pt remain buyer
commerci regulatori clinic ip risk associ market pipelin product
alexion develop market therapi address rare diseas
discount back
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
model updat follow report guidanc revis
kanuma revenu miss estim trim number
out-year bring metabol franchis revenu estim slightli
high end narrow guidanc rang
complement franchis model faster pnh convers soliri
ultomiri consist commentari convers target expect achiev
recal first year ultomiri treatment associ slight price
premium soliri due load dose rais near- mid-term complement
revenu estim also slightli rais mg estim given strong launch
perform partial off-set trim row estim given headwind canada
russian biosimilar net impact chang complement
franchis revenu estim high end new guidanc rang
given manag track record quarterli guidanc rais
comfort remain ahead guidanc
slight tweak expens estim given commentari time
spend expens estim previous rais
 expens estim minor tweak expens
tax bring ep estim guid rang
ep estim increas slightli
appli previous multipl ep discount back
target remain laps partial discount period
slight increas ep think lower multipl appropri given volatil
space
page
collabor agreement
good sold
product sale
total revenu
sell gener administr
total revenu
statement oper
dollar except per share data
provis incom tax tax benefit
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
page
dollar except per share data
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
